Bank of New York Mellon’s Beta Bionics BBNX Stock Holding History

Bank of New York Mellon’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Buy	122,897 +24,093	+24%	+$287K	﹤0.01%	2972
2026 Q1	$990K	Sell	98,804 -979	-1%	-$14.5K	﹤0.01%	3214
2025 Q4	$3.04M	Buy	99,783 +9,665	+11%	+$258K	﹤0.01%	2610
2025 Q3	$1.79M	Buy	90,118 +62,765	+229%	+$1.1M	﹤0.01%	2860
2025 Q2	$398K	Buy	27,353 +1,560	+6%	+$22.1K	﹤0.01%	3633
2025 Q1	$316K	Buy	+25,793	New	+$481K	﹤0.01%	3679

Other funds holding BBNX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Bank of New York Mellon's BBNX Position: Q2 2026 in Review

Bank of New York Mellon increased its Beta Bionics (BBNX) stake by 24% in Q2 2026, buying an estimated $287K and bringing the position to 122,897 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #2972.

Bank of New York Mellon first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.04M in Q4 2025. 63 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

Bank of New York Mellon held 122,897 shares of Beta Bionics worth $1.93M as of Q2 2026.
Bank of New York Mellon bought 24,093 Beta Bionics shares in Q2 2026, an estimated $287K.
Beta Bionics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2972 holding.
Bank of New York Mellon first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
Bank of New York Mellon's Beta Bionics position peaked at $3.04M in Q4 2025.
63 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.